These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 24679900)

  • 21. Parkinson disease clinical subtypes: key features & clinical milestones.
    Campbell MC; Myers PS; Weigand AJ; Foster ER; Cairns NJ; Jackson JJ; Lessov-Schlaggar CN; Perlmutter JS
    Ann Clin Transl Neurol; 2020 Aug; 7(8):1272-1283. PubMed ID: 32602253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sex differences in movement disorders.
    Meoni S; Macerollo A; Moro E
    Nat Rev Neurol; 2020 Feb; 16(2):84-96. PubMed ID: 31900464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases.
    Coughlin DG; Hurtig HI; Irwin DJ
    Mov Disord; 2020 Jan; 35(1):5-19. PubMed ID: 31660655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Motor and non-motor function predictors of mortality in Parkinson's disease.
    Bugalho P; Ladeira F; Barbosa R; Marto JP; Borbinha C; Salavisa M; da Conceição L; Saraiva M; Fernandes M; Meira B
    J Neural Transm (Vienna); 2019 Nov; 126(11):1409-1415. PubMed ID: 31385098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele.
    Shahid M; Kim J; Leaver K; Hendershott T; Zhu D; Cholerton B; Henderson VW; Tian L; Poston KL
    Neurobiol Dis; 2019 Jul; 127():278-286. PubMed ID: 30826425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. State-level prevalence, health service use, and spending vary widely among Medicare beneficiaries with Parkinson disease.
    Mantri S; Fullard ME; Beck J; Willis AW
    NPJ Parkinsons Dis; 2019; 5():1. PubMed ID: 30701188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the clinical features of early Parkinson's disease with comparatively integrated intestinal function.
    Guan X; Wang Y; Li Q; Wei M; Chen L; Cheng O
    Neurol Sci; 2018 Nov; 39(11):1847-1856. PubMed ID: 30019200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Video-fluoroscopic swallowing study scale for predicting aspiration pneumonia in Parkinson's disease.
    Tomita S; Oeda T; Umemura A; Kohsaka M; Park K; Yamamoto K; Sugiyama H; Sawada H
    PLoS One; 2018; 13(6):e0197608. PubMed ID: 29874285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Depression in Parkinson's disease: A case-control study.
    Wu YH; Chen YH; Chang MH; Lin CH
    PLoS One; 2018; 13(2):e0192050. PubMed ID: 29390032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How Wearable Sensors Can Support Parkinson's Disease Diagnosis and Treatment: A Systematic Review.
    Rovini E; Maremmani C; Cavallo F
    Front Neurosci; 2017; 11():555. PubMed ID: 29056899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease.
    De Pablo-Fernandez E; Tur C; Revesz T; Lees AJ; Holton JL; Warner TT
    JAMA Neurol; 2017 Aug; 74(8):970-976. PubMed ID: 28655059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Pharmacological Approaches to Treating Non-Motor Symptoms of Parkinson's Disease.
    Kelberman MA; Vazey EM
    Curr Pharmacol Rep; 2016 Dec; 2(6):253-261. PubMed ID: 28534003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on the treatment of Parkinson's disease psychosis: role of pimavanserin.
    Combs BL; Cox AG
    Neuropsychiatr Dis Treat; 2017; 13():737-744. PubMed ID: 28331324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic analysis of microarray datasets to identify Parkinson's disease‑associated pathways and genes.
    Feng Y; Wang X
    Mol Med Rep; 2017 Mar; 15(3):1252-1262. PubMed ID: 28098893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relevance of gender in Parkinson's disease: a review.
    Picillo M; Nicoletti A; Fetoni V; Garavaglia B; Barone P; Pellecchia MT
    J Neurol; 2017 Aug; 264(8):1583-1607. PubMed ID: 28054129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Premotor Symptoms as Predictors of Outcome in Parkinsons Disease: A Case-Control Study.
    Wu YH; Lee WJ; Chen YH; Chang MH; Lin CH
    PLoS One; 2016; 11(8):e0161271. PubMed ID: 27533053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for Cognitive Impairment in Parkinson's Disease: Improving the Diagnostic Utility of the MoCA through Subtest Weighting.
    Fengler S; Kessler J; Timmermann L; Zapf A; Elben S; Wojtecki L; Tucha O; Kalbe E
    PLoS One; 2016; 11(7):e0159318. PubMed ID: 27437705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and Epidemiological Factors Associated with Mortality in Parkinson's Disease in a Brazilian Cohort.
    Fernandes GC; Socal MP; Schuh AF; Rieder CR
    Parkinsons Dis; 2015; 2015():959304. PubMed ID: 26819798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival in Parkinson's disease. Relation with motor and non-motor features.
    de Lau LM; Verbaan D; Marinus J; van Hilten JJ
    Parkinsonism Relat Disord; 2014 Jun; 20(6):613-6. PubMed ID: 24679900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients.
    Merola A; Zibetti M; Angrisano S; Rizzi L; Ricchi V; Artusi CA; Lanotte M; Rizzone MG; Lopiano L
    Brain; 2011 Jul; 134(Pt 7):2074-84. PubMed ID: 21666262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.